In 2022, more than 2 million cases of lung cancer were recorded, making it the second most prolific cancer in the world.

We are delighted to announce the first Pharmacological Optimization of Lung Cancer Treatment Webinar - Drug-Drug Interactions, Therapeutic Drug Monitoring, and Immunotherapy will take place on 22 April 2024.

Non-small lung cancer (NSCLC) is the most common type of lung cancer, with first-line treatment consisting of small molecule inhibitors (SMIs) and immune/chemotherapy.

With advent of these novel therapies, several pharmacological issues have arisen that need full attention of clinicians, pharmacists and clinical researchers.

The following topics will be discussed during the webinar:

- Drug-Drug Interactions between SMIs and Directly-Acting Oral Anti-coagulants (DOACs) in Patients with Lung Cancer

- Therapeutic Drug Monitoring (TDM) of Small Molecule Inhibitors in Patients with Lung Cancer: Ready for the Clinic?

- Management of toxicities from immunotherapy: an ESMO Clinical Practice Guideline

This webinar is an exciting opportunity for many healthcare professionals – including pulmonologists, medical oncologists, nurse specialists, pharmacists, and clinical pharmacologists – to increase their knowledge about the pharmacological optimization of lung cancer treatment.

For more information and registration see: Pharmacological Optimization of Lung Cancer Treatment Webinar: Drug-Drug Interactions, Therapeutic Drug Monitoring, and Immunotherapy | AME (academicmedicaleducation.com)